TY - JOUR
T1 - Weight Gain and Metabolic Effects in Persons with HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide
AU - Palella, Frank J.
AU - Hou, Qingjiang
AU - Li, Jun
AU - Mahnken, Jonathan
AU - Carlson, Kimberly J.
AU - Durham, Marcus
AU - Ward, Douglas
AU - Fuhrer, Jack
AU - Tedaldi, Ellen
AU - Novak, Richard
AU - Buchacz, Kate
N1 - Funding Information:
Supported by Centers for Disease Control and Prevention Contract Nos. 200-2001-00133, 200-2006-18797, 200-2011-41872, 200-2015-63931, and 75D30120C08752.
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Background:The timing and magnitude of antiretroviral therapy-associated weight change attributions are unclear.Setting:HIV Outpatient Study participants.Methods:We analyzed 2007-2018 records of virally suppressed (VS) persons without integrase inhibitor (INSTI) experience who switched to either INSTI-based or another non-INSTI-based ART, and remained VS. We analyzed BMI changes using linear mixed models, INSTI- and tenofovir alafenamide (TAF) contributions to BMI change by linear mixed models-estimated slopes, and BMI inflection points.Results:Among 736 participants (5316 person-years), 441 (60%) switched to INSTI-based ART; the remainder to non-INSTI-based ART. The mean follow-up was 7.15 years for INSTI recipients and 7.35 years for non-INSTI. Preswitch, INSTI and non-INSTI groups had similar median BMI (26.3 versus 25.9 kg/m2, P = 0.41). INSTI regimens included raltegravir (178), elvitegravir (112), and dolutegravir (143). Monthly BMI increases postswitch were greater with INSTI than non-INSTI (0.0525 versus 0.006, P < 0.001). A BMI inflection point occurred 8 months after switch among INSTI users; slopes were similar regardless of TAF use immediately postswitch. Among INSTI + TAF users, during 8 months postswitch, 87% of BMI slope change was associated with INSTI use, 13% with TAF use; after 8 months, estimated contributions were 27% and 73%, respectively. For non-INSTI+TAF, 84% of BMI gain was TAF-associated consistently postswitch. Persons switching from TDF to TAF had greater BMI increases than others (P < 0.001).Conclusion:Among VS persons who switched ART, INSTI and TAF use were independently associated with BMI increases. During 8 months postswitch, BMI changes were greatest and most associated with INSTI use; afterward, gradual BMI gain was largely TAF-associated.
AB - Background:The timing and magnitude of antiretroviral therapy-associated weight change attributions are unclear.Setting:HIV Outpatient Study participants.Methods:We analyzed 2007-2018 records of virally suppressed (VS) persons without integrase inhibitor (INSTI) experience who switched to either INSTI-based or another non-INSTI-based ART, and remained VS. We analyzed BMI changes using linear mixed models, INSTI- and tenofovir alafenamide (TAF) contributions to BMI change by linear mixed models-estimated slopes, and BMI inflection points.Results:Among 736 participants (5316 person-years), 441 (60%) switched to INSTI-based ART; the remainder to non-INSTI-based ART. The mean follow-up was 7.15 years for INSTI recipients and 7.35 years for non-INSTI. Preswitch, INSTI and non-INSTI groups had similar median BMI (26.3 versus 25.9 kg/m2, P = 0.41). INSTI regimens included raltegravir (178), elvitegravir (112), and dolutegravir (143). Monthly BMI increases postswitch were greater with INSTI than non-INSTI (0.0525 versus 0.006, P < 0.001). A BMI inflection point occurred 8 months after switch among INSTI users; slopes were similar regardless of TAF use immediately postswitch. Among INSTI + TAF users, during 8 months postswitch, 87% of BMI slope change was associated with INSTI use, 13% with TAF use; after 8 months, estimated contributions were 27% and 73%, respectively. For non-INSTI+TAF, 84% of BMI gain was TAF-associated consistently postswitch. Persons switching from TDF to TAF had greater BMI increases than others (P < 0.001).Conclusion:Among VS persons who switched ART, INSTI and TAF use were independently associated with BMI increases. During 8 months postswitch, BMI changes were greatest and most associated with INSTI use; afterward, gradual BMI gain was largely TAF-associated.
KW - integrase inhibitor
KW - metabolic effects
KW - TAF
KW - viral suppression
KW - weight gain
UR - http://www.scopus.com/inward/record.url?scp=85143645560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143645560&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000003101
DO - 10.1097/QAI.0000000000003101
M3 - Article
C2 - 36150045
AN - SCOPUS:85143645560
VL - 92
SP - 67
EP - 75
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
SN - 1525-4135
IS - 1
ER -
